Wednesday, 16 Jan 2019

You are here

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Reuters:Trump assails high drug prices, avoids direct hit on industry  https://reut.rs/2IBaFiY

Bloomber: Trump's Unimpressive Plan to Lower Drug Prices  https://bloom.bg/2I8tkmO

Financial Times: Trump blames foreign countries for high drug prices  https://on.ft.com/2IdPe4c

NY Times: 6 Takeaways From Trump’s Plans to Try to Lower Drug Prices https://nyti.ms/2IEieFS

          Trump’s Plan to Lower Drug Prices Diverges From Campaign Promise  https://nyti.ms/2wyN65D

           Trump to Drop Call for Medicare to Negotiate Lower Drug Prices  https://nyti.ms/2wAmGR1

Wall St. Journal: Trump’s Plan to Cut Drug Prices Leaves Industry Relieved https://on.wsj.com/2IDeAf6

NPR:  Trump Drug Pricing 'Blueprint' Could Take Years To Build  https://n.pr/2IyMRw5

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Price of Drug Promotion Skyrockets

JAMA reports that health care advertising costs in the U.S. have almost doubled over the past two decades, surging from $17.7 billion in 1997 to at least $29.9 billion in 2016. (Citation source: https://buff.ly/2Rk8a9Q)

2018 Rheumatology Year In Review

This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review.  The top 10 list herein is rooted in what rheumatologists should know and what will likely change their standards and practice in the future, if not 2019. 

Best of 2018: Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Best of 2018: Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.

Rising Physician Exclusion from Medicare and Medicaid

JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance. 

Overall the authors found that the number of physicians excluded from Medicare, Medicaid, and other state public insurance programs increased on average by 20% per year between 2007 and 2017.